Role of m⁶A RNA Methylation in Mediating Resistance to Chemotherapy and Immunotherapy in Cancer
Olli Johannes Laaksonen, Mikko Petteri Virtanen
Abstract
The development of resistance to anticancer drugs is a major barrier to successful cancer therapy. Tumors that acquire such resistance often employ intricate molecular strategies to evade pharmacological treatment. Among epigenetic RNA modifications, N6-methyladenosine (m6A) is the most prevalent and reversible. Dysregulation of RNA methyltransferases (“writers”), demethylases (“erasers”), and m6A-binding proteins (“readers”) has been observed in various malignancies, influencing oncoprotein lev
Topics & Concepts
MethyltransferaseEpigeneticsCancer researchRNACancerImmunotherapyMethylationChemotherapyDrug resistanceMedicineDNA methylationBiologyAcquired resistanceRNA methylationCancer chemotherapyCancer cellRNA-binding proteinDownregulation and upregulationAzacitidineHistoneResistance (ecology)Cancer immunotherapyImmunologyBioinformaticsGeneCancer-Associated FibroblastsNegative therapeutic reactionRNA modifications and cancerCancer-related gene regulationEpigenetics and DNA Methylation